Information Provided By: 
Fly News Breaks for July 28, 2016
JAZZ
Jul 28, 2016 | 15:04 EDT
Cowen analyst Ken Cacciatore noted that he has long considered Jazz's 8,772,306 patent as the "most critical component protecting the Xyrem franchise" and he believes that Amneal being denied its request to institute an inter partes review of the patent provides additional comfort. The analyst, who thinks that this decision sets the stage for Jazz and the remaining generic challengers to reach a settlement, recommends investors continue adding to Jazz positions. Cacciatore has a $190 price target and Outperform rating on Jazz shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
